Title: Measurement of MASI score among Libyan melasma patients
Authors: Abdullatif S. Alghwel, Ghada A. Albarghathi, Ali M. Gargoom, Najat H. Belkhair, Gamal A. Duweb
DOI: https://dx.doi.org/10.18535/jmscr/v8i3.16
Abstract
Background: Melasma is a very common skin disorder. It is most common in young women with brownish skin tan, but it can affect anyone. The Melasma Area and Severity Index (MASI), an outcome measure developed to provide a more accurate quantification of the severity of melasma and changes during therapy.
Objectives: The aim of this study to describe the clinico-epidemiological pattern of melasma and to assess the melasma severity by applying MASI score.
Subjects and Methods: One hundred patients with melasma were exposed to detailed disease history and complete dermatological examination and MASI score was calculated.
Results: Out of 100 patients, 89% were female and 11% were male. 66% of the patients the site affected was centrofacial followed by malar that seen in 32%. MASI score was mild in 26% of patients, moderate in 73% of cases and severe in only 1% of the patients.
Conclusion: Melasma in men is definitely less common than in women, but shares the same clinical characteristics as in women. Majority of our patients had moderate MASI score. Among male patient no one had severe MASI score. Forehead and chin regions showed less severe involvement as compare to right and left malar regions.
Keywords: melasma, hyperpigmentation, Melasma Area & Severity Index (MASI).
References
- Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54:303.
- Hilde Lapeere, et al. hypomelanoses and hypermelanoses. In Fitzpatricks dermatology in general medicine, 7th Ed, edited by Klaus Wolf et al. McGraw-Hill companies , 2008; 73: 635.
- Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994;130:727-33.
- Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011; 64:78-83.
- Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin 2003; 21: 689–697.
- Pichardo R, , Vallejo Q and Arcury TA. The Prevalence of Melasma and Its Association with Quality of Life among Adult Male Migrant Latino Workers. Journal dermatology, 2009, 48(1):22-26.
- Grimes PE, Stockton T. Pigmentary disorders in blacks. Dermatol Clin 19 8 8; 6: 271– 281.
- Lee CS, Lim HW. Cutaneous diseases in Asians. Dermatol Clin 2003; 21: 669–677.
- James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
- Draelos ZD. Melasma: introduction and disease background. In: Flucinolone Acetonide, Hydroquinone and Tretinoin: Unique and Effective Combination Treatment for Melasma. 2001. Virtual Symposium CD-ROM.
- James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
- Balkrishnan R, McMichael AJ, Hu JY, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol 2006; 45: 111–115.
- Hacer Uyanikoglu and Mustafa Aksoy. Quality of life in patients with melasma in Turkish women. Dermatol Reports 2017; 9(2):7340.